VISTA, CA – July 1st, 2013 – Leica Biosystems, the global leader in ePathology solutions, announced today the launch of the Aperio AT2, its highly innovative image capture device.
“The Aperio AT2 provides the benefit of increasing efficiency by reducing the need for pathologists to travel or to ship slides,” said Jared N. Schwartz, M.D., Ph.D., F.C.A.P., Leica Biosystems’ chief medical officer. “Further, we’re pleased that the technology built into the Aperio AT2 reduces overhead and technician hours spent in front of the image capture device, proven by the tissue finding accuracy, focusing, automated magnification selection, and less than 2% rescan rate – all aimed to achieve a very high-sustained throughput.”
Providing the highest throughput with a small footprint, the Aperio AT2 also offers seamless integration with network sharing and precision decision support tools that enhance laboratory efficiencies, reduce turn-around-time and improve analytic confidence. Increased productivity in the entire lab is now possible with practical, fit for purpose, Aperio ePathology Solutions.
According to Dr. Eric Glassy, medical director, Pathology, Inc. and senior pathologist, APMG, “ePathology holds the promise of moving beyond ordinary reviews to truly collaborative pathology. The old, passive Hub-and-Spoke mode of sending out glass slides and waiting for a fax will give way to a broadly linked digital network of experts. Instant access to the best minds in Pathology is finally possible.”
About Leica Biosystems
Leica Biosystems is a global leader in laboratory workflow solutions for anatomic pathology, striving to advance cancer diagnostics to improve patients’ lives. Leica Biosystems provides a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. Recognizing there is a shortage of pathology expertise worldwide, as well as increasing subspecialization, Leica Biosystems expanded its capability in pathology imaging with Aperio ePathology Solutions enabling greater access for pathologists through market leading whole slide scanners, Network solutions that enables remote, real-time viewing and easy distribution of images for collaboration and Precision solutions that provide pathologists with easy-to-use quantitative image analysis to improve clinical and research productivity, reproducibility and consistency. Leica Biosystems is represented in over 100 countries. It has manufacturing facilities in 6 countries, sales and service organizations in 19 countries, and an international network of dealers. Further information can be found at http://www.LeicaBiosystems.com.